Join us at Health Research Day — June 6th at Canton Waterfront Park, Baltimore!   Learn More →
← Back to all trials
Not Yet Recruiting NCT05598788

Microsampling Approach for Monitoring of Kinase Inhibitor Targeted Therapies

Conditions: Blood Concentrations of Nine Anti-cancer Drugs : Axitinib, Olaparib, regorafénib, Cabozantinib, Niraparib, Talazoparib, Palbociclib, Abemaciclib, Tucatinib

Sex: All
Ages: 18 Years – N/A
Enrollment: 360
Sponsor: Rennes University Hospital

Location: France

Summary

The MISTIK project aims at clinically validating the technique of oral anticancer drugs determination by volumetric absorptive micro-sampling and at comparing the results to measurements performed on venous samples.

Eligibility Criteria

Inclusion Criteria:Patients treated with one of the 9 drugs concerned by the study : axitinib, olaparib, regorafénib, cabozantinib, niraparib, talazoparib, palbociclib, abemaciclib, tucatinibperson who does not object to their participation in the researchExclusion Criteria:Adults subject to legal protection (safeguard of justice, curatorship, guardianship), persons deprived of their liberty

Interested in this study? View the official listing for contact and enrollment details.

View on ClinicalTrials.gov

Source: ClinicalTrials.gov (NCT05598788). StuddyBuddy aggregates publicly available trial information.